Lixte Biotechnology (LIXT): Rentabilitas dodolan miturut bathi resik

Logo perusahaan publik Lixte Biotechnology Holdings Inc. (LIXT)

Lixte Biotechnology's development of antitumor agents remains independent of market fluctuations, relying instead on scientific testing cycles. Patent protection of compounds creates a defensive barrier, although the commercial potential of preclinical stages remains uncertain. ESG principles and bioethics are integrated into the production processes. This net profitability chart on GURU.Markets reflects the business's resilience, where 0.00 shows the current value of the metric.

LIXT: Tingkat bathi resik lixte.com 04.07.2022 - 06.07.2026

Lixte Biotechnology Holdings (LIXT) - rincian metrik lan laporan keuangan

- rega saham lan prakiraan rega para ahli:
Analisis komprehensif perusahaan:Lixte Biotechnology
Barang unggulan Lixte Biotechnology Holdings Inc.

Long-term capital requires strict control over a business's ability to generate real cash flow. This is critical for Lixte Biotechnology (LIXT), as the development of oncology drugs is currently funded by existing reserves. By analyzing net profit margins, an investor can see the profit share of every dollar of revenue. This chart reflects final efficiency after deducting all operating and tax expenses. Negative values confirm a stage of active capital burn.